Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

NDAQ:MRNA) Moderna, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRNA ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.